Complete Guide to Sacituzumab Govitecan (Trodelvy) Pharmacokinetics

Overview

Sacituzumab Govitecan (Trodelvy) is a Antibody-Drug Conjugate (ADC) used in the Oncology therapeutic area. It is indicated for Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. Population PK simulator for sacituzumab govitecan (SG, Trodelvy) — TROP2-directed ADC for TNBC, HR+/HER2- breast cancer, and urothelial cancer. Triple-analyte model: intact ADC, free SN-38 payload (with UGT1A1 genotype covariate), and total antibody with time-dependent clearance. Based on Sathe et al. Clin Pharmacokinet 2024.

Mechanism of Action

Sacituzumab Govitecan (Trodelvy) exerts its pharmacological effect by targeting TROP2. As a Antibody-Drug Conjugate (ADC), it modulates this target to achieve therapeutic efficacy in Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.

Key Pharmacokinetic Parameters

This Population PK (Triple-analyte: ADC + SN-38 payload + total antibody) model for Sacituzumab Govitecan (Trodelvy) characterizes the time-course of drug concentrations following IV Infusion administration. Key parameters such as clearance (CL), volume of distribution (Vd), and absorption rate constant (Ka) define the drug's disposition. Use the interactive simulator below to explore these parameters in detail.

Dosing & Administration

Sacituzumab Govitecan (Trodelvy) is administered via the IV Infusion route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.

Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, C_max, and C_trough.

Clinical Considerations

In the Oncology therapeutic area, for the treatment of Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload, understanding the pharmacokinetics of Sacituzumab Govitecan (Trodelvy) is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Sacituzumab Govitecan (Trodelvy) pharmacokinetics include:

• •Body weight and body composition
• •Renal and hepatic function
• •Drug-drug interactions and concomitant medications
• •Age, sex, and genetic polymorphisms
• •Anti-drug antibody (ADA) formation and immunogenicity

Frequently Asked Questions